Idiopathic Generalized Epilepsy - Part 3

In part one of this series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss insights from the LATE-MT trial that was presented at the 2026 European Stroke Organization Conference. Read more about LATE-MT trial. 

Dr. Shuvro Roy and Dr. Michael Levy discuss satralizumab for treating relapsing MOGAD, current management challenges, and the encouraging results of this new therapy. Read more about this abstract. 

Send comments and feedback

In the second episode of our genetics and epilepsy series, Sharp Waves explores how genetic insights can inform considerations and outcomes ...

In 2016, the estimated number of people globally with active epilepsy was 45.9 million. For the US in 2015, this figure was around 3.4 million. So epilepsy is common and generalised seizures are a common type of epilepsy. And the consequences can be serious - from medication side ...  Show more

Send comments and feedback

Sudden Unexpected Death in Epilepsy (SUDEP) affects about one out of every 1.000 people with epilepsy.  Despite its rarity, SUDEP is important to dis ...

Send comments and feedback

In this episode, we explore the science behind exercise as an adjunct treatment for epilepsy and debunk some common myths (spoiler alert: With very r ...